The DESCAR-T registry was set up at the request of the health authorities to improve our knowledge of CAR T-cell therapies marketed in France to treat patients diagnosed with hematological malignancies. The objective of this registry is to collect data on the efficacy as well as on short- and long-term tolerance of these therapies in real-life setting.
Thanks to the data collected, the registry makes it possible to carry out projects to answer specific research questions. One of these projects is looking at the efficacy and safety of CAR T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL) after failure of at least two previous lines of therapy.
Why is this study being implemented?
Current treatments for DLBCL can achieve a complete remission in a majority of patients. However, in some patients, these treatments are not always effective. CAR-T treatments are a new chance for a cure for these patients who have had little or no response to previous lines of treatment.
What are the objectives of the study?
The study aims to describe the real-world profile of DLBCL patients who have received CAR T-cell therapy following at least two prior lines of systemic therapy. It specifically focuses on patients with an incomplete response to CAR T-cell therapy. The analyses will enhance understanding of their outcomes, help identify potential prognostic factors, and contribute to improving the overall therapeutic approach.
How will the study be carried out?
This project was initiated by Dr. Guillaume MANSON and Dr. Rémy DULERY in order to analyze the data from the DESCAR-T registry.
The report of this study has been sent to the project leaders who will only receive descriptive results without individual data. No link can be established between the data contained in the report and the patients whose data is collected in DESCAR-T.
This study was carried out in the last quarter of 2023 and the results were communicated through an oral presentation at the French Society of Hematology (SFH) congress in March 2024.
FOR PATIENTS WHO HAVE BEEN OFFERED CAR-T THERAPY IN FRANCE
What does this project mean for you?
This project concerns patients included in the DESCAR-T registry, diagnosed with Diffuse Large B-Cell Lymphoma, for whom CAR T-cell therapy has been considered (outside clinical trials) in France after two other lines of treatment for this disease.
If you are in this situation and agree for your data to be used for this project, this has no direct implications for you.
What should you do about this study?
- If you would like more information about the processing of your data in the context of DESCAR-T and this project,
Or
- if you wish to exercise your rights regarding your data (access and rectification, limitation of their use),
⇒ inform the doctor at your hospital or centre of care for CAR T-cell therapy, who will contact LYSARC while maintaining your anonymity. You can also notify your decision by email at: dpo@lysarc.org.
- Otherwise, you don’t have to do anything.
You can find more information about your rights in relation to your data “I am participating or have participated in a trial“.